The main goals of therapy in AL amyloidosis

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the primary goals of therapy in light chain (AL) amyloidosis. The main objective is to improve survival by achieving a profound hematologic response. Complete response (CR) and very good partial response (VGPR) are key targets, as they are associated with better survival outcomes. The role of anti-amyloid agents is still under investigation, with ongoing studies expected to provide further insights. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.